# Immunological corollary of the pulmonary mycobiome

European Respiratory Journal
52, 1800766
DOI: 10.1183/13993003.00766-2018

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Bronchiectasis. Nature Reviews Disease Primers, 2018, 4, 45. | 18.1 | 181 |
| 2 | Inhaled nanomaterials and the respiratory microbiome: clinical, immunological and toxicological perspectives. Particle and Fibre Toxicology, 2018, 15, 46. | 2.8 | 84 |
| 3 | Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet, The, 2018, 392, 880-890. | 6.3 | 247 |
| 4 | Treatable traits in bronchiectasis. European Respiratory Journal, 2018, 52, 1801269. | 3.1 | 84 |
| 5 | MycopathologiaGENOMES: The New â€˜Homeâ€™ for the Publication of Fungal Genomes. Mycopathologia, 2019, 184, 551-554. | 1.3 | 25 |
| 6 | Treatment to prevent exacerbations in bronchiectasis: macrolides as first line?. European Respiratory Journal, 2019, 54, 1901213. | 3.1 | 8 |
| 7 | Optimisation and Benchmarking of Targeted Amplicon Sequencing for Mycobiome Analysis of Respiratory Specimens. International Journal of Molecular Sciences, 2019, 20, 4991. | 1.8 | 28 |
| 8 | Intranasal Inoculation of Cryptococcus neoformans in Mice Produces Nasal Infection with Rapid Brain Dissemination. MSphere, 2019, 4, . | 1.3 | 22 |
| 9 | The Human Lung Mycobiome in Chronic Respiratory Disease: Limitations of Methods and Our Current Understanding. Current Fungal Infection Reports, 2019, 13, 109-119. | 0.9 | 28 |
| 10 | Bronchiectasis and cough: An old relationship in need of renewed attention. Pulmonary Pharmacology and Therapeutics, 2019, 57, 101812. | 1.1 | 5 |
| 11 | Functional effects of the microbiota in chronic respiratory disease. Lancet Respiratory Medicine,the, 2019, 7, 907-920. | 5.2 | 269 |
| 12 | The human lung and Aspergillus: You are what you breathe in?. Medical Mycology, 2019, 57, S145-S154. | 0.3 | 53 |
| 13 | The biology of pulmonary exacerbations in bronchiectasis. European Respiratory Review, 2019, 28, 190055. | 3.0 | 48 |
| 14 | Hot topics and current controversies in non-cystic fibrosis bronchiectasis. Breathe, 2019, 15, 286-295. | 0.6 | 9 |
| 15 | The microbiome in bronchiectasis. European Respiratory Review, 2019, 28, 190048. | 3.0 | 68 |
| 16 | Airway microbiome composition correlates with lung function and arterial stiffness in an age-dependent manner. PLoS ONE, 2019, 14, e0225636. | 1.1 | 26 |
| 17 | Distinct â€œImmunoallertypesâ€•of Disease and High Frequencies of Sensitization in Nonâ€“Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 842-853. | 2.5 | 57 |
| 18 | The microbiome in bronchiectasis: Cutting a lung story short. Respirology, 2020, 25, 43-44. | 1.3 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The Mycobiome in Health and Disease: Emerging Concepts, Methodologies and Challenges. Mycopathologia, 2020, 185, 207-231. | 1.3 | 50 |
| 20 | Detection of the â€˜Big Fiveâ€™ mold killers of humans: Aspergillus, Fusarium, Lomentospora, Scedosporium and Mucormycetes. Advances in Applied Microbiology, 2020, 110, 1-61. | 1.3 | 35 |
| 21 | The Roles of Bacteria and Viruses in Bronchiectasis Exacerbation: A Prospective Study. Archivos De Bronconeumologia, 2020, 56, 621-629. | 0.4 | 9 |
| 22 | The Fungal Microbiome and Asthma. Frontiers in Cellular and Infection Microbiology, 2020, 10, 583418. | 1.8 | 35 |
| 23 | The Domestic Environment and the Lung Mycobiome. Microorganisms, 2020, 8, 1717. | 1.6 | 9 |
| 24 | Sensors and Analytical Technologies for Air Quality: Particulate Matters and Bioaerosols. Chemistry - an Asian Journal, 2020, 15, 4241-4255. | 1.7 | 24 |
| 25 | The Interactions of Airway Bacterial and Fungal Communities in Clinically Stable Asthma. Frontiers in Microbiology, 2020, 11, 1647. | 1.5 | 22 |
| 26 | A Refined View of Airway Microbiome in Chronic Obstructive Pulmonary Disease at Species and Strain-Levels. Frontiers in Microbiology, 2020, 11, 1758. | 1.5 | 36 |
| 27 | Pathogen and host genetics underpinning cryptococcal disease. Advances in Genetics, 2020, 105, 1-66. | 0.8 | 5 |
| 28 | The airway fungal microbiome in asthma. Clinical and Experimental Allergy, 2020, 50, 1325-1341. | 1.4 | 31 |
| 29 | Environmental fungal sensitisation associates with poorer clinical outcomes in COPD. European Respiratory Journal, 2020, 56, 2000418. | 3.1 | 44 |
| 30 | Evaluation of Droplet Digital Polymerase Chain Reaction (ddPCR) for the Absolute Quantification of Aspergillus species in the Human Airway. International Journal of Molecular Sciences, 2020, 21, 3043. | 1.8 | 19 |
| 31 | Whole-Genome Sequencing of Aspergillus terreus Species Complex. Mycopathologia, 2020, 185, 405-408. | 1.3 | 7 |
| 32 | Increased Chitotriosidase Is Associated With Aspergillus and Frequent Exacerbations in South-East Asian Patients With Bronchiectasis. Chest, 2020, 158, 512-522. | 0.4 | 15 |
| 33 | The Roles of Bacteria and Viruses in Bronchiectasis Exacerbation: A Prospective Study. Archivos De Bronconeumologia, 2020, 56, 621-629. | 0.4 | 32 |
| 34 | Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 433-447. | 2.5 | 58 |
| 35 | A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD. European Respiratory Journal, 2021, 57, 2002050. | 3.1 | 44 |
| 36 | The airway microbiome in COPD, bronchiectasis and bronchiectasisâ€COPD overlap. Clinical Respiratory Journal, 2021, 15, 123-133. | 0.6 | 35 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Sensitization to AÂfumigatus in subjects with nonâ€cystic fibrosis bronchiectasis. Mycoses, 2021, 64, 412-419. | 1.8 | 12 |
| 38 | The Healthy Airway Mycobiome in Individuals of Asian Descent. Chest, 2021, 159, 544-548. | 0.4 | 11 |
| 39 | HUMAN MYCOBIOME IN NORMOBIOSIS AND DYSBIOSIS STATES CHARACTERISTICS AND ANALYSIS METHODS. Postepy Mikrobiologii, 2021, 60, 31-46. | 0.1 | 0 |
| 40 | Airway bacterial and fungal microbiome in chronic obstructive pulmonary disease. Medicine in Microecology, 2021, 7, 100035. | 0.7 | 6 |
| 41 | Respiratory Mycoses in COPD and Bronchiectasis. Mycopathologia, 2021, 186, 623-638. | 1.3 | 15 |
| 42 | Integrative microbiomics in bronchiectasis exacerbations. Nature Medicine, 2021, 27, 688-699. | 15.2 | 105 |
| 43 | The pulmonary mycobiomeâ€"A study of subjects with and without chronic obstructive pulmonary disease. PLoS ONE, 2021, 16, e0248967. | 1.1 | 16 |
| 44 | Pseudomonas aeruginosa in bronchiectasis: infection, inflammation, and therapies. Expert Review of Respiratory Medicine, 2021, 15, 649-662. | 1.0 | 19 |
| 45 | Allergic fungal airways disease (AFAD): an under-recognised asthma endotype. Mycopathologia, 2021, 186, 609-622. | 1.3 | 28 |
| 46 | Aspergillus-Associated Endophenotypes in Bronchiectasis. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 556-566. | 0.8 | 6 |
| 47 | Bronchiectasis Exacerbations: Definitions, Causes, and Acute Management. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 595-605. | 0.8 | 6 |
| 48 | Pathophysiology of Bronchiectasis. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 499-512. | 0.8 | 17 |
| 49 | The lung microbiome in lung transplantation. Journal of Heart and Lung Transplantation, 2021, 40, 733-744. | 0.3 | 17 |
| 50 | The Airway Microbiome: Present and Future Applications. Archivos De Bronconeumologia, 2022, 58, 8-10. | 0.4 | 19 |
| 51 | High Frequency of Allergic Bronchopulmonary Aspergillosis in Bronchiectasis-COPD Overlap. Chest, 2022, 161, 40-53. | 0.4 | 8 |
| 52 | The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study. Lancet Respiratory Medicine,the, 2021, 9, 885-896. | 5.2 | 63 |
| 53 | Future Directions for Clinical Respiratory Fungal Research. Mycopathologia, 2021, 186, 685-696. | 1.3 | 3 |
| 54 | Fungal Infections and ABPA. Respiratory Medicine, 2020, , 93-126. | 0.1 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Obstructive lung diseases and allergic bronchopulmonary aspergillosis. Current Opinion in Pulmonary Medicine, 2021, 27, 105-112. | 1.2 | 9 |
| 56 | From culturomics to metagenomics: the mycobiome in chronic respiratory diseases. , 2019, , 88-118. | | 7 |
| 58 | The Lung Microbiome during Health and Disease. International Journal of Molecular Sciences, 2021, 22, 10872. | 1.8 | 72 |
| 61 | Aspergillus-related lung disease in people with cystic fibrosis: can imaging help us to diagnose disease?. European Respiratory Review, 2021, 30, 210103. | 3.0 | 6 |
| 62 | The current understanding and future directions for sputum microbiome profiling in chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 2022, 28, 121-133. | 1.2 | 11 |
| 65 | Early life inter-kingdom interactions shape the immunological environment of the airways. Microbiome, 2022, 10, 34. | 4.9 | 16 |
| 66 | Microbiology and the Microbiome in Bronchiectasis. Clinics in Chest Medicine, 2022, 43, 23-34. | 0.8 | 10 |
| 67 | Diagnosis and Evaluation of Bronchiectasis. Clinics in Chest Medicine, 2022, 43, 7-22. | 0.8 | 7 |
| 68 | Bronchiectasis from 2012 to 2022. Clinics in Chest Medicine, 2022, 43, 1-6. | 0.8 | 5 |
| 69 | A cliniciansâ€™ review of the respiratory microbiome. Breathe, 2022, 18, 210161. | 0.6 | 9 |
| 70 | Clinical characteristics of patients with bronchiectasis with nontuberculous mycobacterial disease in Mainland China: a single center cross-sectional study. BMC Infectious Diseases, 2021, 21, 1216. | 1.3 | 4 |
| 71 | Impacts of Nontuberculous Mycobacteria Isolates in Non-cystic Fibrosis Bronchiectasis: A 16-Year Cohort Study in Taiwan. Frontiers in Microbiology, 2022, 13, 868435. | 1.5 | 5 |
| 72 | The Human Mycobiome in Chronic Respiratory Diseases: Current Situation and Future Perspectives. Microorganisms, 2022, 10, 810. | 1.6 | 9 |
| 80 | Clinical Aspergillus Signatures in COPD and Bronchiectasis. Journal of Fungi (Basel, Switzerland), 2022, 8, 480. | 1.5 | 12 |
| 81 | Mycobiota composition and changes across pregnancy in patients with gestational diabetes mellitus (GDM). Scientific Reports, 2022, 12, . | 1.6 | 8 |
| 82 | The human lung microbiomeâ€”A hidden link between microbes and human health and diseases. , 2022, 1, . | | 15 |
| 83 | Sensitisation to recombinantAspergillus fumigatusallergens and clinical outcomes in COPD. European Respiratory Journal, 2023, 61, 2200507. | 3.1 | 7 |
| 84 | The respiratory microbiota alpha-diversity in chronic lung diseases: first systematic review and meta-analysis. Respiratory Research, 2022, 23, . | 1.4 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 85 | A lung pathobiont story: Thinking outside the Kochâ€™s postulate box. Cell Host and Microbe, 2022, 30, 1196-1198. | 5.1 | 3 |
| 86 | Neisseria species as pathobionts in bronchiectasis. Cell Host and Microbe, 2022, 30, 1311-1327.e8. | 5.1 | 17 |
| 87 | Diagnosis values of Dectin-1 and IL-17 levels in plasma for invasive pulmonary aspergillosis in bronchiectasis. Frontiers in Cellular and Infection Microbiology, 0, 12, . | 1.8 | 0 |
| 88 | Human airway and lung microbiome at the crossroad of health and diseaseÂ(Review). Experimental and Therapeutic Medicine, 2022, 25, . | 0.8 | 2 |
| 89 | Aspergillussensitisation: an underappreciated treatable trait in airway disease. European Respiratory Journal, 2023, 61, 2202042. | 3.1 | 0 |
| 90 | Distinct community structures of the fungal microbiome and respiratory health in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2023, , . | 0.3 | 3 |
| 92 | Endotypes in bronchiectasis: moving towards precision medicine. A narrative review. Pulmonology, 2023, 29, 505-517. | 1.0 | 5 |
| 93 | The Fungal and Bacterial Interface in the Respiratory Mycobiome with a Focus on Aspergillus spp.. Life, 2023, 13, 1017. | 1.1 | 2 |
| 105 | The microbiome and COPD. , 2024, , 118-134. | | 0 |